Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) announced that its management team will present at the TD Cowen Immunology & Inflammation Summit, held virtually on November 12-13, 2025. The company presentation is scheduled for Thursday, November 13, 2025 at 1:30pm ET.
Management will also hold one-on-one investor meetings. A live webcast is available at the provided link and a replay will be accessible for 90 days via the company’s Investor Calendar.
Vera Therapeutics (NASDAQ: VERA) submitted a BLA through the FDA Accelerated Approval Program for atacicept to treat adults with immunoglobulin A nephropathy (IgAN) on November 7, 2025.
Submission is supported by a prespecified interim analysis of the Phase 3 ORIGIN 3 trial showing a 46% reduction from baseline in 24‑hour UPCR and a 42% reduction versus placebo at week 36 (p<0.0001). The company reports a favorable safety profile comparable to placebo. ORIGIN 3 enrolled 431 adults and remains blinded to assess eGFR over two years, with trial completion expected in 2027.
Vera Therapeutics (Nasdaq: VERA) announced that on November 4, 2025 its Compensation Committee granted inducement awards to six new employees under the 2024 Inducement Plan.
The awards include non-qualified stock options to purchase 79,050 shares and restricted stock units covering 39,915 shares. Each option has an exercise price of $24.35, equal to Vera Therapeutics’ closing price on November 4, 2025.
Vesting: options vest over four years with 25% on the first anniversary then monthly over 36 months; RSUs vest over four years with 25% vesting on each anniversary beginning November 20, 2025. Awards are subject to the Inducement Plan and applicable award agreements and were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) reported positive ORIGIN Phase 3 interim data for atacicept in IgA nephropathy presented at ASN Kidney Week 2025 and published in NEJM.
At week 36 atacicept produced a 46% reduction from baseline in UPCR and a 42% reduction versus placebo (p<0.0001). Secondary results included Gd-IgA1 reduced 68% and hematuria resolved in 81% of participants with baseline hematuria. Safety across the ORIGIN program was described as comparable to placebo, with fewer serious adverse events (1 [0.5%] atacicept vs 11 [5%] placebo) and no deaths.
The company plans a BLA submission via Accelerated Approval in Q4 2025 with a potential PDUFA date in 2026; the ORIGIN 3 trial (N=431) remains blinded to assess two-year eGFR results expected in 2027.
Vera Therapeutics (NASDAQ: VERA) reported Q3 2025 results and a business update ahead of ASN Kidney Week 2025. The company will present 36‑week ORIGIN 3 primary endpoint results as a late‑breaking oral presentation on November 6, 2025, with two additional posters also scheduled.
Vera expects to submit a BLA for atacicept in IgA nephropathy to the U.S. FDA via the Accelerated Approval Program in Q4 2025, with a potential U.S. commercial launch in 2026. Ongoing trials include PIONEER, a monthly dose range finding study, and ORIGIN Extend. Initial PIONEER results are expected in Q4 2025; 2‑year ORIGIN 3 data are expected in 2027.
Financials: Q3 net loss was $80.3M ($1.26/diluted share); nine‑month operating cash use was $171.1M. Cash, equivalents, and marketable securities totaled $497.4M as of September 30, 2025.
Vera Therapeutics (Nasdaq: VERA) will host an investor call and webcast on November 6, 2025 at 4:30 PM ET to review data from the ORIGIN Phase 3 trial of atacicept for IgA nephropathy (IgAN) presented at the morning plenary of ASN Kidney Week 2025.
Management will be joined by Jonathan Barratt, MD, PhD, FRCP and Richard Lafayette, MD, FACP. A live Q&A will follow. The webcast replay will be available for 90 days via the company’s Investor Calendar. Registration is required.
Vera Therapeutics (Nasdaq: VERA) announced that data from the Phase 3 ORIGIN trial of atacicept in IgA nephropathy (IgAN) will be presented as a featured late-breaking oral presentation in the Opening Plenary at ASN Kidney Week 2025 in Houston.
The oral presentation (Abstract TH-OR083) will be delivered by Richard Lafayette, MD on Thursday, November 6, 2025 from 9:02 AM–9:14 AM CST in Hall A. Two informational posters (INFO12-TH and INFO13-TH) on ORIGIN Extend and PIONEER will be available the same day from 10:00 AM–12:00 PM CST in the Exhibit Hall.
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards granted by its Compensation Committee on October 6, 2025 to 21 new employees under the 2024 Inducement Plan.
The grants consist of 135,100 non‑qualified stock options and 70,775 restricted stock units (RSUs). Each option has an exercise price of $30.94, equal to Vera Therapeutics’ closing price on October 6, 2025. Options vest over four years with 25% after one year and monthly vesting over the following 36 months. RSUs vest 25% on each anniversary beginning November 20, 2025, over four years. Awards are subject to the Inducement Plan and individual award agreements and to continued service through vesting dates.
Vera Therapeutics (Nasdaq: VERA) announced inducement grants to eight new employees under its 2024 Inducement Plan. The grants include non-qualified stock options to purchase 85,000 shares of Class A common stock at $21.90 per share and restricted stock units (RSUs) for 45,250 shares.
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting from either August 20 or November 20, 2025. All grants are subject to continued employment with Vera.
Vera Therapeutics (NASDAQ: VERA), a late clinical-stage biotechnology company focused on immunological disease treatments, has announced its participation in two upcoming investor conferences in New York.
The company will participate in the Cantor Global Healthcare Conference on September 4, 2025, at 9:10am ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 5:35pm ET. Both events will feature fireside chats and one-on-one meetings with management.
A webcast replay will be accessible for 90 days through the company's website.